ONWARD Medical: US commercial launch sparks momentum, driving 23% YTD surge
ONWARD's stock has surged by ~+23% YTD, marking its highest level in recent memory. This rally reflects the company’s latest milestone: its first commercial sales in the US, announced last week (here). The news follows the de novo clearance of the ARC-EX System in December 2024 (read our note here)
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.